Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Mar 2:340:c712.
doi: 10.1136/bmj.c712.

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

Sholom Wacholder  1 , Bingshu Eric Chen, Allen Wilcox, George Macones, Paula Gonzalez, Brian Befano, Allan Hildesheim, Ana Cecilia Rodríguez, Diane Solomon, Rolando Herrero, Mark Schiffman; CVT group
Collaborators, Affiliations
Randomized Controlled Trial

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

Sholom Wacholder et al. BMJ. .

Abstract

Objective: To assess whether vaccination against human papillomavirus (HPV) increases the risk of miscarriage.

Design: Pooled analysis of two multicentre, phase three masked randomised controlled trials

Setting: Multicentre trials in several continents and in Costa Rica.

Participants: 26 130 women aged 15-25 at enrolment; 3599 pregnancies eligible for analysis.

Interventions: Participants were randomly assigned to receive three doses of bivalent HPV 16/18 VLP vaccine with AS04 adjuvant (n=13 075) or hepatitis A vaccine as control (n=13 055) over six months.

Main outcome measures: Miscarriage and other pregnancy outcomes.

Results: The estimated rate of miscarriage was 11.5% in pregnancies in women in the HPV arm and 10.2% in the control arm. The one sided P value for the primary analysis was 0.16; thus, overall, there was no significant increase in miscarriage among women assigned to the HPV vaccine arm. In secondary descriptive analyses, miscarriage rates were 14.7% in the HPV vaccine arm and 9.1% in the control arm in pregnancies that began within three months after nearest vaccination.

Conclusion: There is no evidence overall for an association between HPV vaccination and risk of miscarriage.

Trial registration: Clinical Trials NCT00128661 and NCT00122681.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Vaccine was provided for CVT by GSK Biologicals, under a clinical trials agreement with NCI. GSK also provided support for aspects of the trial associated with regulatory submission needs of the company under FDA BB-IND 7920. Douglas Lowy and John Schiller from NCI are named inventors on US government owned HPV vaccine patents that are licensed to GSK and Merck, and so are entitled to limited royalties as specified by federal law. None of the other NCI and Costa Rica co-authors have any potential conflicts of interest to report. The researchers are completely independent from the non-government funders and sponsors. After a planned interim analysis, including safety review, of PATRICIA in December 2006, the data and safety monitoring board (DSMB) of CVT requested an assessment of possible effects of the vaccine on miscarriages by performing a pooled post hoc analysis of data from the two parallel trials. GSK provided data on pregnancy for this miscarriage analysis from PATRICIA to the statistician for CVT (SW). Two outside consultants (GM and AW), who are experts in reproductive epidemiology, helped in the preparation of the analysis and report. Both the data and safety monitoring board and the independent data monitoring committee (IDMC), which oversees CVT and PATRICIA trials, respectively, recommended that NCI statistician prepare a manuscript describing the results for publication in the scientific literature. GSK scientists provided background information and data from PATRICIA, and provided suggestions on the methods, analysis and interpretation. CVT investigators from NCI and Costa Rica prepared this manuscript with input from the expert and consultants. GSK scientists commented on draft manuscripts, but the named authors made the final decisions about its content.

Figures

None
Fig 1 Follow-up through data freeze points (20 Dec 2007 for CVT and 31 Jan 2008 for PATRICIA) for women and pregnancies leading to 373 miscarriages. In CVT three women received wrong vaccination (one in HPV group and two in hepatitis A group) and were classified according to intention to treat; one woman randomised twice was excluded. Recent pregnancies were defined as those that began within one year of data freeze point
None
Fig 2 Miscarriage rates for both arms and differences according to time between nearest vaccination and estimated date of conception. Of 3599 pregnancies included in analysis, 187 (5.2%) had estimated conception date before nearest vaccination. Estimations of conception assume that ovulation occurs on day 14 after last menstrual period, though 10% of cycles have ovulation at day 24 or later. Among 187 pregnancies with conception ostensibly before vaccination, many had conception dates only a few days before vaccination (median 10 days). Given that all pregnant women had negative hCG test results at time of vaccination (based on highly sensitive β hCG assays), most subsequent pregnancies had probably been conceived after relatively late ovulations and conception had occurred after vaccination. Thus, these data do not provide useful data on the question of vaccine safety before conception (HAV=hepatitis A vaccine)
See this image and copyright information in PMC

Comment in

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. - PubMed
    1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907. - PubMed
    1. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70. - PubMed
    1. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27. - PubMed
    1. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43. - PubMed

Publication types

MeSH terms

Substances

Associated data